Abstract
Objective
To examine whether urine kynurenine (KYN) levels were associated with early-stage Parkinson’s disease (PD), as well as the value of urine KYN as a potential biomarker in early-stage PD.
Method
Eighty-two participants including 41 PD patients and 41 healthy controls were enrolled into this study. Urine KYN levels were measured with a KYN enzyme-linked immunoassay kit. In order to explore the correlation between some clinical parameters and urine KYN, the clinical parameters for these participants were recorded. Diagnostic value and clinical relevance of urine KYN were assessed by using receiver operator characteristic (ROC) curve and correlation analysis.
Results
Urine KYN levels were significantly higher in the PD group than in the healthy group (891.95 ± 276.65 pg/ml vs. 640.11 ± 122.37 pg/ml, p = 0.000). The correlations between urine KYN levels and clinical parameters are as follows: Hoehn-Yahr stage (r = 0.676, p = 0.000), disease duration (r = 0.772, p = 0.000), Mini-Mental State Examination scores (r = −0.434, p = 0.005). There was no statistically significant correlation between urine KYN with age, low-density cholesterol (LDL), triglycerides (TG), cholesterol (TC), homocysteine (HCY), uric acid (UA), and glomerular filtration rate (GFR). The ROC analysis showed that urine KYN optimal cutoff value of 751.88 pg/ml had a sensitivity of 65.9% and a specificity of 90.2% for distinguishing between PD and controls, with an area under the curve (AUC) of 0.776.
Conclusion
Urine KYN were significantly associated with PD severity and mild cognitive impairment. Urine KYN may be a new biomarker for early-stage PD.
Similar content being viewed by others
References
Halbach OB, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson’s disease. Prog Neurobiol 73(3):151–177. https://doi.org/10.1016/j.pneurobio.2004.05.002
Yazar T, Yazar HO, Zayimoğlu E, Çankaya S (2018) Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson’s disease. Neurol Sci 39:1415–1421. https://doi.org/10.1007/s10072-018-3439-6
Elbaz A, Carcaillon L, Kab S, Moisan F (2016) Epidemiology of Parkinson’s disease. Rev Neurol 172:14–26. https://doi.org/10.1017/S0317167100046321
Xu XM, Dong MX, Feng X, Liu Y, Pan JX, Jia SY, Cao D, Wei YD (2018) Decreased serum proNGF concentration in patients with Parkinson’s disease. Neurol Sci 39:91–96. https://doi.org/10.1007/s10072-017-3157-5
Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Bio Med 62(5):132–144. https://doi.org/10.1016/j.freeradbiomed.2013.01.018
Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Cannas A, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Costanzo AM, Gualberti G, Melzi G, di Luzio Paparatti U, Antonini A (2016) Motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. Neurol Sci 37:1785–1792. https://doi.org/10.1007/s10072-016-2664-0
Debapriya, Garabadu, Nidhi (2019) Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. Behav Pharmacol 30(8):642–652
Zhong RX, Qin YJ, Chen ZY, Zhang JT, Zhao SZ et al (2019) Progress in pathogenesis and early diagnosis of Parkinson’s disease. Clin Med 35(3):276–280. https://doi.org/10.3760/cma.j.issn.1008-6315.2019.03.019
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Tan L, Yu JT, Tan L (2012) The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci 323:1–2. https://doi.org/10.1016/j.jns.2012.08.005
Widner B, Leblhuber F, Fuchs D (2002) Increased neopterin production and tryptophan degradation in advanced Parkinson’s disease. J Neural Transm 109(2):181–189. https://doi.org/10.1007/s007020200014
Tang YM, Zhang FF, Liu Y, Chang DD, Ren YP (2011) Significance of kynurenine, kynurenic acid and tryptophan in patients with Parkinson’s disease. Guangdong Med J 32(13):1678–1681. https://doi.org/10.3969/j.issn.1001-9448.2011.13.013
Schwarcz R, Stone TW (2016) The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology 112:234–247. https://doi.org/10.1016/j.neuropharm.2016.08.003
Maximilian TA, Lilly S, Robert S, Michel G, Sophie E et al (2018) Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: relevance for schizophrenia. Neuropharmacology 138:130–139. https://doi.org/10.1016/j.neuropharm.2018.06.003
Rossi F, Miggiano R, Ferraris D, Rizzi M (2019) The synthesis of kynurenic acid in mammals: an updated kynurenine aminotransferase structural KATalogue. Front Mol Biosci 6:7. https://doi.org/10.3389/fmolb.2019.00007
Albuquerque EX, Schwarcz R (2013) Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol 85(8):1027–1032. https://doi.org/10.1016/j.bcp.2012.12.014
Linderholm KR, Alm MT, Larsson MK, Olsson SK, Goiny M, Hajos M, Erhardt S, Engberg G (2015) Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons. Neuropharmacology 102:42–47. https://doi.org/10.1016/j.neuropharm.2015.10.028
Ramos-Chávez LA, Lugo HR, González ED, Pineda B, Ríos C et al (2018) Relevance of alternative routes of kynurenic acid production in the brain. Oxidative Med Cell Longev 2018:1–14. https://doi.org/10.1155/2018/5272741
Katalin S, Szabó E, Vécsei L (2018) Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection. Molecules 23(1):191. https://doi.org/10.3390/molecules23010191
Guillemin GJ (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279(8):1356–1365. https://doi.org/10.1111/j.1742-4658.2012.08485.x
Gulaj E, Pawlak K, Bien B, Pawlak D (2010) Kynurenine and its metabolites in Alzheimer’s disease patients. Advances in Medical Sciences 55(2):204–211. https://doi.org/10.2478/v10039-010-0023-6
Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130:226–238. https://doi.org/10.1016/j.pharmthera.2011.01.014
Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L (2005) Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. J Neurol Sci 239(1):31–35. https://doi.org/10.1016/j.jns.2005.07.006
Zadori D, Klivényi P, Plangár I, Toldi J, Vécsei L (2011) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. Cell Mol Med 15:701–717. https://doi.org/10.1111/j.1582-4934.2010.01237.x
Lim CK, Fernández-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S, Bessede A, Fernandez-Villalba E, Zinger A, Herrero MT, Guillemin GJ (2016) Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease. Prog Neurobiol 155:76–95. https://doi.org/10.1016/j.pneurobio.2015.12.009
Chess AC, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophren Bull 33:797–804. https://doi.org/10.1093/schbul/sbl033
Young S, Koo H, Kim et al (2018) Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism contributes to poststroke depression induced in mice by ischemic stroke along with spatial restraint stress. Oxidative Medicine & Cellular Longevity 2018:241384–241315. https://doi.org/10.1155/2018/2413841
Ilzecka J, Kocki T, Stelmasiak Z, Turski WA (2003) Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand 107:412–418. https://doi.org/10.1034/j.1600-0404.2003.00076.x
Beal MF, Matson WR, Storey E, Milbury P, Ryan EA et al (1992) Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J Neurol Sci 108(1992):80–87. https://doi.org/10.1016/0022-510X(92)90191-M
Hartai Z, Klivenyi P, Janaky T, Penke B, Vecsei L (2005) Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand 112(2):93–96. https://doi.org/10.1111/j.1600-0404.2005.00442.x
Rejdak K, Bartosik-Psujek H, Dobosz B, Kocki T, Grieb P, Giovannoni G., Turski W.A., Stelmasiak Z. (2002) Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett 331(1):0–65. https://doi.org/10.1016/s0304-3940(02)00710-3, 63
Rejdak K, Petzold A, Kocki T, Kurzepa J, Grieb P, Turski WA, Stelmasiak Z (2007) Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J Neural Transm 114(8):1011–1015. https://doi.org/10.1007/s00702-007-0667-y
Havelund JF, Andersen AD, Binzer M, Blaabjerg M, Heegaard NHH, Stenager E, Faergeman NJ, Gramsbergen JB (2017) Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J Neurochem 142:745–766. https://doi.org/10.1111/jnc.14104
Cheng ML, Chang KH, Wu YR, Chen CM (2016) Metabolic disturbances in plasma as biomarkers for Huntington disease. J NutrBiochem 31:38–44. https://doi.org/10.1016/j.jnutbio.2015.12.001
Lewitt PA, Li J, Lu M, Beach TG, Adler CH et al (2013) 3-hydroxykynurenine and other Parkinson’s disease biomarkers discovered by metabolomic analysis. Mov Disord 28(12):1653–1660. https://doi.org/10.1002/mds.25555
Funding
This research was supported by National Natural Science Foundation of China (81400957), and the Medical and Health Technology Development Project of Shandong (2016WSA10008).
Author information
Authors and Affiliations
Contributions
Putting forward this idea: Yong-peng Yu
Project administration: Yong-peng Yu
Data curation and methodology: Jia-he Bai and Ya-li Zheng
Software and writing, review, and editing: Jia-he Bai and Yong-peng Yu
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was approved by the institutional Ethics Board Committee of the Weihai Central Hospital. All participants provided written informed consent to participate in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bai, Jh., Zheng, Yl. & Yu, Yp. Urinary kynurenine as a biomarker for Parkinson’s disease. Neurol Sci 42, 697–703 (2021). https://doi.org/10.1007/s10072-020-04589-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-020-04589-x